COVID-19 UPDATE

Contact

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

Financials & Filings

Filing date	Description	Form	Filing Group	Issuer	View
Jun 25, 2007	25-NSE	25-NSE	Other	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001354457-07-000187.pdf 0001354457-07-000187.rtf
Jun 22, 2007	25-NSE	25-NSE	Other	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001296945-07-000009.pdf 0001296945-07-000009.rtf
Jun 16, 2004	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001193125-04-103997.pdf 0001193125-04-103997.rtf 0001193125-04-103997.xls
Jun 09, 2006	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001193125-06-127453.pdf 0001193125-06-127453.rtf 0001193125-06-127453.xls
Jun 06, 2008	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001193125-08-129739.pdf 0001193125-08-129739.rtf 0001193125-08-129739.xls
Sep 06, 2001	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0000950144-01-506642.pdf 0000950144-01-506642.rtf 0000950144-01-506642.xls
Jun 05, 2009	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001193125-09-126288.pdf 0001193125-09-126288.rtf 0001193125-09-126288.xls
Jun 13, 2007	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001193125-07-134982.pdf 0001193125-07-134982.rtf 0001193125-07-134982.xls
Jun 01, 2011	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001193125-11-156354.pdf 0001193125-11-156354.rtf 0001193125-11-156354.xls
Jun 17, 2003	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001096906-03-000353.pdf 0001096906-03-000353.rtf 0001096906-03-000353.xls

Data provided by Kaleidoscope.

Recent BDSI News

BioDelivery Sciences Reports Second Quarter 2021 Results August 4, 2021

Total Company Net Revenue of $41.4 Million Driven by BELBUCA ® All-Time High TRx Market Share Strong Profitability with GAAP Net Income of $9.1 Million , or $0.09 per share, EBITDA Margin of 32%, and Non-GAAP Net Income of $12.5 Million , or $0.12 per Share, Drives Operating Cash Generation of $9.2 ...

BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine August 4, 2021

The only FDA-approved, ready-to-use oral solution for the acute treatment of migraine with or without aura in adults First step to building a growth platform in Neurology Patent protection until 2036 RALEIGH, N.C. , Aug. 04, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , ...

BioDelivery Sciences to Report Second Quarter 2021 Financial Results on August 4, 2021 July 22, 2021

RALEIGH, N.C. , July 22, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its second quarter 2021 ...

More news

More events

Stay Connected

Stay up to date on the latest news

Get started now